Sangart, Inc. is a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents. Dr. Robert Winslow, a world-renowned authority in the field of hemoglobin and oxygen transport, founded Sangart after having spent more than two decades at the Letterman Army Institute of Research and University of California at San Diego studying and defining red blood cell substitutes and mechanisms of oxygen transport by cell-free hemoglobin solutions. The discoveries arising from this research on the effective action of oxygen transport agents have been patented and published in numerous scientific articles and form the basis for Sangart’s technologies.

Sangart’s approach to the development of oxygen transport agents employs novel technologies and is based on more than two decades of research into the mechanism of oxygen transport by cell-free hemoglobin.

Sangart’s lead product, Hemospan®, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Because of the critical role oxygenation plays in the human body, Hemospan® has the potential to be used to treat a wide variety of medical conditions.

Sangart was founded in 1998 and is located in San Diego, California.